Cancer Home > Drug Interactions With Eribulin
Several drugs can cause negative interactions with eribulin, including other chemotherapy medications and QT-prolonging medicines. Combining these products may increase your risk for serious problems, such as low white blood cells, anemia, or changes in heart rhythm. Before receiving an infusion, tell your healthcare provider about any other medications, vitamins, or supplements you are taking.
An Overview of Eribulin InteractionsEribulin mesylate (Halaven™) is a prescription medication licensed to treat breast cancer. This medication may react with certain other medications.
Some of the drugs that may lead to interactions with eribulin include but are not limited to:
- Other chemotherapy medications
- Medications that can cause a specific change in the heart rhythm known as QT prolongation (see QT-Prolonging Medications for a list of such medications).
Drug Interactions With Eribulin ExplainedThe following sections explain in detail the potentially negative reactions that can occur when eribulin is combined with any of the drugs listed above.
Other Chemotherapy Medications
Most chemotherapy medications have a tendency to cause similar serious side effects, such as low white blood cells, nausea, and anemia. Combining eribulin with other chemotherapy drugs might increase the risk of severe side effects. Your healthcare provider will take this into account when anticipating and treating any side effects that may occur.
In studies, eribulin was shown to potentially cause a change in heart rhythm known as QT prolongation. This is a potentially serious change that can lead to life-threatening arrhythmias. Combining eribulin with other medications that have this potential probably increases the risk. If you must combine eribulin with other QT-prolonging medications, your healthcare provider should closely monitor your heart rhythm.